It is well known that men are reluctant to see a doctor, especially a urologist. As a result, there is a risk that prostate ...

The market expects Quest Diagnostics (DGX) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus ...

Quest Diagnostics DGX is set to release its first-quarter 2025 results on April 22, before the market opens. The renowned ...

BofA analyst Michael Ryskin raised the firm’s price target on Quest Diagnostics (DGX) to $198 from $190 and keeps a Buy rating on the shares.

A new, error-corrected method for detecting cancer from blood samples is much more sensitive and accurate than prior methods and may be useful for monitoring disease status in patients following ...

About 1,200 B.C. LifeLabs employees have been on rotating strikes since Feb. 16. On Monday, four of 10 locations in or near ...

The United States government has discontinued its free at-home COVID-19 test program after four years. The program, which began in 2021, shipped over 900 million tests directly to U.S. households.

Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, including advanced diagnostics for brain health, today announced the launch of a new laboratory blood test designed to help ...

The sample is then sent to a Quest Diagnostics laboratory for testing, with results shared electronically with both the physician and patient. While the service is not intended to replace pelvic ...